港股異動丨香港醫思醫療(2138.HK)一度漲近5% 擬收購醫學實驗室測試服務
格隆匯12月15日丨香港醫思醫療(2138.HK)一度漲近5%,高見6.36港元,創約一年半新高,現漲3.47%,最新總市值65億港元。香港醫思醫療集團今早公佈,公司有條件收購栢立醫學化驗所有限公司75%股權,總代價為3.375億港元,包括2.295億元現金;及將配售價值1.08億港元股份。栢立醫學化驗所有限公司於香港經營五間醫療實驗室,並擁有逾40名全職註冊醫療實驗室技術專家。栢立醫學化驗所有限公司已成立逾40年,其專業水平得到醫療專業人士及政府機關認可。目標公司為香港政府認可的首個本地COVID-19核酸檢測機構之一。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.